Literature DB >> 12800480

Insulin therapy for the critically ill patient.

Greet Van den Berghe1.   

Abstract

The risk of mortality or significant morbidity is high among critically ill patients who are treated in the intensive care unit (ICU) for > 5 days. These patients are susceptible to sepsis, excessive inflammation, critical illness polyneuropathy, and multiple organ failure, the latter often being the cause of death. Most intensive care patients, even those who did not previously suffer from diabetes, are hyperglycemic, which is presumed to reflect an adaptive development of insulin resistance. In the K.U. Leuven study it was hypothesized that hyperglycemia is not a beneficial adaptation to severe illness but rather predisposes patients to many of the typical intensive care complications--prolonged intensive care dependence and death. The effects of intensive insulin therapy to maintain normoglycemia during critical illness were studied in a large group (N = 1548) of ventilated, surgical ICU patients. An algorithm was proposed for implementing this procedure. The randomly assigned intensive insulin therapy group received insulin infusion tailored to control blood glucose (BG) levels in the range 80-110 mg/dL, whereas the conventional treatment group received insulin only when glucose levels exceeded 200 mg/dL, and in that event were maintained in a target range of 180-200 mg/dL. Intensive insulin therapy induced a 43% reduction of intensive care mortality risk (P = 0.036 after correction for interim analyses) and a 34% reduction of hospital mortality (P = 0.005). A reduced risk of severe infections by 46% (P = 0.003) was associated with a 35% reduction in prolonged (> 10 d) requirement for antibiotic therapy (P < 0.001). In addition, excessive inflammation was prevented. Logistic regression analysis indicated that control of BG levels, rather than insulin administration itself, likely explains the observed clinical benefits. Use of insulin infusion to maintain normoglycemia using a titration algorithm, at least in populations similar to those in the Leuven study, improves outcome. Further data are needed to establish the applicability of this strategy to other patient groups, such as those in a medical ICU and in general hospital care.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12800480     DOI: 10.1016/s1098-3597(03)90018-4

Source DB:  PubMed          Journal:  Clin Cornerstone        ISSN: 1873-4480


  17 in total

1.  Improving outcomes in patients with acute coronary syndromes.

Authors:  Mustafa Tiewala; Alexander Perkevald; Cristina Ogrin; Mary Ann Banerji
Journal:  Curr Diab Rep       Date:  2004-06       Impact factor: 4.810

Review 2.  [Preoperative long-term therapy].

Authors:  K Buhre; L de Rossi; W Buhre
Journal:  Anaesthesist       Date:  2005-09       Impact factor: 1.041

Review 3.  Pituitary function during severe and life-threatening illnesses.

Authors:  C Gauna; G H van den Berghe; A J van der Lely
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 4.  Critical illness polyneuropathy and myopathy in the intensive care unit.

Authors:  Wolfgang Zink; Rainer Kollmar; Stefan Schwab
Journal:  Nat Rev Neurol       Date:  2009-07       Impact factor: 42.937

Review 5.  [Treatment of hyperglycemia in adult, critically ill patients].

Authors:  Martin Clodi; Michael Resl; Heidemarie Abrahamian; Bernhard Föger; Raimund Weitgasser
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

6.  Guidelines for perioperative care in elective rectal/pelvic surgery: Enhanced Recovery After Surgery (ERAS(®)) Society recommendations.

Authors:  J Nygren; J Thacker; F Carli; K C H Fearon; S Norderval; D N Lobo; O Ljungqvist; M Soop; J Ramirez
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

7.  Duration of time on intensive insulin therapy predicts severe hypoglycemia in the surgically critically ill population.

Authors:  Nathan T Mowery; Oliver L Gunter; Rondi M Kauffmann; Jose J Diaz; Bryan C Collier; Addison K May
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

8.  [Antihyperglycaemic therapy in critically ill patients].

Authors:  Martin Clodi; Michael Resl; Heidemarie Abrahamian; Bernhard Föger; Raimund Weitgasser
Journal:  Wien Klin Wochenschr       Date:  2012-12       Impact factor: 1.704

9.  Insulin decreases inflammatory signal transcription factor expression in primary human liver cells after LPS challenge.

Authors:  Marc G Jeschke; Dagmar Klein; Wolfgang E Thasler; Ulrich Bolder; Hans-Jürgen Schlitt; Karl-Walter Jauch; Thomas S Weiss
Journal:  Mol Med       Date:  2008 Jan-Feb       Impact factor: 6.354

Review 10.  Complications and monitoring - Guidelines on Parenteral Nutrition, Chapter 11.

Authors:  W H Hartl; K W Jauch; K Parhofer; P Rittler
Journal:  Ger Med Sci       Date:  2009-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.